Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
2 hedge funds and large institutions have $471K invested in Sonnet BioTherapeutics in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
229% more capital invested
Capital invested by funds: $143K → $471K (+$328K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$233K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19K |
| 2 |
VF
Virtu Financial
New York
|
-$15K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4K |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Ameriprise
Minneapolis,
Minnesota
| $251K | +$233K | +2 | New |
|
|
2
Citadel Advisors
Miami,
Florida
| $80K | +$117K | +1 | New |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $35K | – | – | – |
|
4
Renaissance Technologies
New York
| $27K | – | – | – |
|
|
IC
5
Intersect Capital
San Ramon,
California
| $21K | – | – | – |
|
6
Dimensional Fund Advisors
Austin,
Texas
| $20K | – | – | – |
|
7
BlackRock
New York
| $19K | – | – | – |
|
8
Bank of America
Charlotte,
North Carolina
| $9K | – | – | – |
|
|
FEG
9
Financial Enhancement Group
Anderson,
Indiana
| $6K | – | – | – |
|
|
QCIG
10
Quad-Cities Investment Group
Davenport,
Iowa
| $3K | – | – | – |
|
|
11
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$1K | – | – |
|
|
12
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$19K | – | – |
|
|
13
UBS Group
Zurich,
Switzerland
| – | -$4K | – | – |
|
|
VF
14
Virtu Financial
New York
| – | -$15K | – | – |
|
SONN Hedge Fund Activity: Q1 2019 in Review
2 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q1 2019, worth a combined $471K — up 229% from $143K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SONN positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Ameriprise, opening a new position worth an estimated $233K. The largest seller was Susquehanna International Group, cutting an estimated $19K.
- 2 institutional investors held Sonnet BioTherapeutics (SONN) as of Q1 2019, up from 0 in Q4 2018.
- Funds reported $471K of Sonnet BioTherapeutics stock for Q1 2019, up 229% quarter-over-quarter.
- 2 funds opened new Sonnet BioTherapeutics positions in Q1 2019 and 0 closed out, a net change of +2 holders.
- The largest Sonnet BioTherapeutics buyer in Q1 2019 was Ameriprise, an estimated $233K added.
- The largest Sonnet BioTherapeutics seller in Q1 2019 was Susquehanna International Group, an estimated $19K sold.
Based on aggregated 13F filings for Q1 2019.